ArticleContact dermatitis2026
Impact of Allergic Contact Dermatitis on Health-Related Quality of Life: A Cross-Sectional Case-Control Study in a Spanish Population.
Article in Contact dermatitis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Broadening the View: Substance P and Its Metabolism in Pruritus-Related Diseases.The Journal of dermatology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundAllergic contact dermatitis (ACD) is a chronic inflammatory skin disorder associated with substantial impairment in quality of life (QoL). Few studies have comprehensively assessed the multidimensional impact of ACD using validated QoL instruments and healthy controls.
objectivesTo evaluate the impact of ACD on QoL compared to a control group and to explore the association between clinical variables and patient-reported outcomes.
methodsThis cross-sectional study included 225 patients with confirmed ACD (positive and clinically relevant patch tests) and 225 healthy controls. All participants completed the Dermatology Life Quality Index (DLQI), the EuroQoL-5D (EQ-5D-5L) and the Skindex-29. Disease severity was assessed using the modified Investigator's Global Assessment (mIGA). Statistical analyses included nonparametric Mann-Whitney U tests for between-group comparisons, correlation analyses, and multivariate linear and ordinal regression models to identify predictors of quality-of-life impairment.
resultsPatients with ACD showed significantly greater impairment across all QoL measures compared to controls (p < 0.001). Pruritus was the most frequently reported symptom (45.0%), and emotional distress and functional limitations were prominent. Higher mIGA scores were significantly associated with poorer QoL across all instruments.
conclusionsACD has a marked negative impact on multiple dimensions of QoL, comparable to that observed in other chronic dermatoses. These findings underscore the importance of integrating standardised QoL assessments into the routine management of ACD and support the adoption of multidimensional approaches in both clinical evaluation and therapeutic decision-making, while also highlighting the relevance of psychosocial screening as an essential component of comprehensive patient care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.